Jeremy L. Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses data from the COVID-19 and Cancer Consortium cohort study, which included patients with active or prior hematologic or invasive solid malignancies, reported across academic and community sites (Abstract LBA110).
Suresh S. Ramalingam, MD, of Emory University, discusses a 3-year update from the CheckMate 227, Part 1, trial, which showed that nivolumab plus ipilimumab continued to provide durable and long-term overall survival benefit vs platinum-doublet chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (Abstract 9500).
Sarah A. Holstein, MD, PhD, of the University of Nebraska Medical Center, discusses top myeloma abstracts from the ASCO20 Virtual Scientific Program: the ENDURANCE trial on carfilzomib, lenalidomide, dexamethasone, and bortezomib; the STaMINA study on transplantation strategies; a first-in-human study on the novel CELMoD agent CC-92480 plus dexamethasone; the CARTITUDE-1 trial on CAR T-cell therapy; and a phase I study of teclistamab (Abstracts LBA3, 8506, 8500, 8505, and 100).
Parameswaran Hari, MD, of the Medical College of Wisconsin, discusses data from four trials and their clinical implications for the treatment of patients with multiple myeloma: the KarMMa and EVOLVE studies on CAR T cell therapies; SWOG-1211 on bortezomib, lenalidomide, and dexamthasone with/without elotuzumab for newly diagnosed, high-risk disease; and the GMMGCONCEPT trial on isatuximab, carfilzomib, lenalidomide, and dexamethasone in front-line treatment (Abstracts 8503, 8504, 8507, 8508).
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated clear cell renal cell carcinoma as well as responses in other VHL-related lesions (Abstract 5003).
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance and new format.
